LLY Lilly (Eli)

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Discovery, development, manufacturing, and marketing of human pharmaceutical products globally
• • New emphasis on LillyDirect digital platform, growing portion of sales in 2025, expanding direct-to-patient access and partnerships

Risk Factors

• • Government price controls per Inflation Reduction Act causing Medicare drug price reductions for Jardiance (2026) and Trulicity, Verzenio (2028), accelerating revenue erosion
• • U.S. market access risk from CVS Caremark removing preferred coverage for Zepbound on some insurance plans in July 2025

Management Discussion & Analysis

• • Revenue $65.2B in 2025, up 45% YoY from $45.0B in 2024, driven by Mounjaro and Zepbound volume growth
• • Gross margin 83.0% in 2025 vs 81.3% in 2024; net income $20.6B (+95% YoY), EPS $22.95 (+96%)

Management Discussion & Analysis

• • Cash and cash equivalents $9.79B as of Sept 30, 2025 vs $3.27B at Dec 31, 2024
• • Total debt $42.51B as of Sept 30, 2025, up $8.86B from $33.64B at Dec 31, 2024

Risk Factors

• • New litigation charge from acquisition of Verve triggered asset impairment and restructuring charges of $365M for Q3 2025, up from $82M prior year
• • Effective tax rate decreased to 22.8% in Q3 2025 from 38.9% in Q3 2024, impacted by lower non-deductible acquired IPR&D charges

What are the latest LLY SEC filings in 2026?

Lilly (Eli) (LLY) has filed a 10-K annual report on February 12, 2026, a 10-Q quarterly report on October 30, 2025, an 8-K current report on April 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did LLY file its most recent 10-K annual report?

Lilly (Eli) (LLY) filed its most recent 10-K annual report on February 12, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view LLY 10-Q quarterly reports?

Lilly (Eli) (LLY)'s most recent 10-Q quarterly report was filed on October 30, 2025. SignalX displays every LLY 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has LLY filed recently?

Lilly (Eli) (LLY)'s most recent 8-K was filed on April 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find LLY insider trading activity (Form 4)?

SignalX aggregates every LLY Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does LLY file with the SEC?

Lilly (Eli) (LLY) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new LLY filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Lilly (Eli) (LLY).

What is LLY's SEC CIK number?

Lilly (Eli) (LLY)'s SEC CIK (Central Index Key) number is 59478. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 59478 to look up all LLY filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find LLY return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Lilly (Eli) (LLY) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.